Tirzepatide for Treatment of CCCA

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 27 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised at 2 of 2 sites
    • Publications: details revised at 9 of 9 entries
  2. Start date: Aug 23, 2026 to Sep 15, 2026v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this pilot clinical trial is to learn if tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults. The main questions it aims to answer are: * Does tirzepatide improve the symptoms and signs of active CCCA? * Does tirzepatide change the activity of genes in the scalp, especially genes related to scarring? * Does tirzepatide promote hair regrowth? Participants will: * Inject tirzepatide once a week for 12 months. * Visit the clinic for scalp examinations, photographs, and other health assessments. * Have scalp biopsies at the beginning of the study and after 6 months of treatment. * Have blood tests and other safety monitoring during the study. There is no separate comparison group. Researchers will compare each participant's results during treatment with the participant's results at the beginning of the study.
Trial Details
NCT Number NCT07734870
Lead Sponsor Johns Hopkins University
Collaborators: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Eli Lilly and Company
Conditions
(from sponsor)		 Central Centrifugal Cicatricial Alopecia (CCCA)
Related terms Alopecia, Insulin Resistance
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov